Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is a medical technology company with a strong financial position and innovative patented technology platform. The company just initiated a pilot study for its extended-wear ECG patch that can detect ischemia outside of traditional medical settings, has a cash position of $12.4M after a successful public offering, and plans to expand into heart attack detection. This strategic focus on decentralized cardiovascular diagnostics, efficient practice-level sales, and potential commercialization through concierge medicine gives HeartBeam a positive outlook for the future, making it a strong buy with a bright future ahead.

Bears say

HeartBeam is facing several risks that could impact its potential for commercial success, including potential failures in clinical trials for additional indications, challenges in achieving commercial success due to market size, and dilution risk. The company also reported a net loss of $4.7 million in 1Q26 and does not expect meaningful revenue until 2H26. There is also the risk of slower sales ramp-up and the reliance on a patient-pay model for early commercialization, potentially hindering broader adoption. While HeartBeam has a strong intellectual property portfolio and has signed commercial partnerships with prestigious medical practices, competition from larger companies in the remote cardiac monitoring space may pose a threat to its market positioning. Overall, the current estimated market value of $168 million and projected revenue of $500-$1,000 per patient do not seem to justify the risks involved, leading to a negative outlook on HeartBeam's stock.

HeartBeam (BEAT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.